- £182.83bn
- £201.95bn
- $54.07bn
- 85
- 18
- 77
- 67
REG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - KOMET Phase III trial met primary endpoint
AnnouncementREG - AstraZeneca PLC - AstraZeneca invests $3.5 billion in US
AnnouncementREG - AstraZeneca PLC - Dato-DXd new BLA submitted, NSQ BLA withdrawn
AnnouncementREG - AstraZeneca PLC - 9M and Q3 2024 Results
AnnouncementREG - AstraZeneca PLC - Tezspire nasal polyps trial met primary endpoints
AnnouncementREG - AstraZeneca PLC - AZN share price movement
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - AZN China President under investigation
AnnouncementREG - AstraZeneca PLC - Wainzua recommended for approval in the EU
AnnouncementRCS - Redx Pharma plc - Preclinical Data on RXC008 Presented at UEG Week
AnnouncementREG - AstraZeneca PLC - AstraZeneca licenses lipid lowering Lp(a) asset
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Tagrisso US approval in unresectable lung cancer
AnnouncementREG - AstraZeneca PLC - Fasenra recommended for EU approval in EGPA
AnnouncementREG - AstraZeneca PLC - Final OS results reported for TROPION-Breast01
AnnouncementREG - AstraZeneca PLC - FluMist approved for self-administration in US
AnnouncementREG - AstraZeneca PLC - Fasenra EGPA US FDA approval
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
Announcement